WASHINGTON — President Trump released an executive order Sunday that would drastically cut how much Medicare pays for virtually all of the drugs seniors take — the boldest move yet he’s taken to lower drug prices since taking office.

The policy vastly expands an older, controversial drug pricing policy that Trump has been teasing for months. Effectively, it will force drug makers to offer their medicines to Medicare at the same prices they do in other countries, as a so-called most favored nations policy. Where an earlier version would only have applied to Part B drugs, which are administered in doctors offices, the new version also applies to Part D drugs, which are sold in pharmacies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • There is a cancer within the whole drug pricing problem. This cancer that want’s things to stay the same is PCMA
    and the PBM’s. Why doesn’t our legislators see how many billions of dollars this country would save if the PBM’s
    didn’t take their vig? Or the extortion money that the PBM’s collect for “proper placement on a drug formulary”.
    This by the way is what PCMA defines drug rebate money as. Total transparency is what is needed. Until the PBM’s
    are governed to adhere to fair and equal laws for all, the price of drugs in this country will never be controlled.

    You go to a doctor, he prescribes the medication he feels will best treat your illness. You then go to get it filled at the pharmacy and your told that the drug isn’t covered. Why the hell not !! Well the PBM’s aren’t getting their payoff.
    So your told that this drug or that drug is covered, but that drug is 5x the price !! So you tell me, who is practicing
    medicine in this country?????

  • Global drug pricing is the poster child for how a product should NOT be priced. It’s been so screwed up for so long, no executive order is going to fix it.

    Price fixing is so widespread, and so entrenched, it may never get unraveled.

    The American consumer — and it’s healthy consumer by and large — basically subsidizes pharmaceutical research for the rest of the globe. Meanwhile, the Euro nations, with their socialized health care, hold the drug companies hostage and say, “here is what we will pay, otherwise, forget it.” The Pharma industry shrugs its shoulders and goes along.

    Third world nations are poor, and so for combination purposes of Public Relations and arguably appropriately humanitarian concerns, they get stuff for next to nothing.

    Medicare, OUR version of socialized medicine, says, “here is what we will pay, otherwise, forget it.” The Pharma industry shrugs its shoulders and goes along.

    So after this game of pricing musical chairs, the American insurance industry, which funds most of health care in this nation, dicks around and will pay for this treatment here, but not that treatment there.

    To truly fix this problem, you would have to get governments — ALL governments — out of the health care/drug pricing business. Moreover, you would need to have extended patent protection so pharma businesses — and they are BUSINESSES, alas — can maintain ownership of easily replicated products, which most drugs are.

    But it will never happen because, you know, “health care is a human right.”

    Economists like to talk about “frictionless markets.” The market for drugs is so full of friction that it’s a wonder we get new drugs at all.

  • one sided bias article with zero data ; in year 2018 UC citizens spent 365 BILLION on drugs or 3 to 5 x what any other country spends on drugs per capita ; furthermore the VA spends 70 % less on the same drugs that Medicare participants pay for drugs with many on fixed incomes and can not afford even the copays ; drug prices have risen faster than inflation for 40 years ; finally the proposed Big Pharma 100 billion in savings over 10 years is less than 3% per year so if they raise them 4% the savings are nullified ; all facts

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy